HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials

Area of Science:

• Virology
• Oncology
• Immunotherapy

Background:

• Herpes simplex virus 1 (HSV-1) serves as a genetic foundation for oncolytic viruses (OVs) in cancer therapy.
• Engineered oHSV variants are designed to minimize neurotoxicity while maximizing anti-tumor effects and immune stimulation.
• The FDA-approved oncolytic HSV-1, talimogene laherparepvec (T-VEC), highlights the clinical potential of this approach.

Purpose of the Study:

• To review recent clinical trial outcomes for oncolytic HSV-1 therapies.
• To provide an outlook on novel HSV-1 oncolytic variants under development.
• To discuss advancements in tumor selectivity, replication efficiency, and immunostimulatory capacity of oHSV.

Main Methods:

• Review of current clinical trial data for oncolytic HSV-1.
• Analysis of newly developed HSV-1 oncolytic virus variants.
• Assessment of tumor selectivity, replication, and immunostimulatory properties.

Main Results:

• Several oHSV variants are in clinical trials, with some showing promising results.
• Ongoing research focuses on enhancing oHSV's tumor-specific activity and immune-priming capabilities.
• The landscape of oncologic therapies may expand with the successful development of new oHSV candidates.

Conclusions:

• Oncolytic HSV-1 represents a significant area of development in cancer treatment.
• Future oHSV variants aim for improved efficacy through enhanced tumor targeting and immunogenicity.
• Clinical studies are crucial for validating the therapeutic potential of these advanced oncolytic viruses.